Isomorphic Labs, the artificial intelligence-powered drug discovery company backed by Alphabet, has raised $5 billion in a Series C funding round as it prepares to move its first drug candidates toward clinical trials. The funding, co-led by Greenoaks and Sequoia Capital, represents a major investment in AI-driven pharmaceutical research as the company seeks to turn computational drug design into treatments that could eventually reach patients.

The London-based company plans to use the capital to expand its proprietary AI drug-design engine, advance its pipeline of potential medicines, strengthen its biological research capabilities and build infrastructure for clinical development. The fundraising comes only months after its previous $2.1 billion round, highlighting investors’ growing interest in AI companies attempting to transform drug discovery and pharmaceutical development.

Isomorphic Labs Raises $5 Billion In Series C Funding

The $5 billion Series C financing was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz also joined the round alongside several other investors, while Alphabet continued its significant backing of the company.

Existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, also participated in the financing.

The funding gives Isomorphic Labs additional resources to scale its drug discovery platform and expand its research programs across multiple therapeutic areas. The company did not publicly disclose its valuation alongside the funding announcement.

The fundraising follows a $2.1 billion Series B round announced in May 2026, led by Thrive Capital. The rapid succession of large funding rounds reflects the capital-intensive nature of AI-driven drug discovery, where companies need to invest in computing infrastructure, scientific research, experimental validation and clinical development.

Isomorphic Labs Funding Details

Funding detailInformation
Funding roundSeries C
Amount raised$5 billion
AnnouncementNovember 17, 2026
Lead investorsGreenoaks and Sequoia Capital
Other new investorsAndreessen Horowitz and others
Existing investorsAlphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and UK Sovereign AI Fund
Previous funding round$2.1 billion Series B
HeadquartersLondon, United Kingdom
Founder and CEODemis Hassabis

AI Drug Discovery Engine Is At The Center Of Its Strategy

Isomorphic Labs is developing its proprietary Isomorphic Drug Design Engine, known as IsoDDE, which combines multiple AI models and simulation systems to help researchers design potential drug molecules.

Traditional drug discovery is a complex process that involves identifying disease mechanisms, selecting targets, designing molecules, testing their biological activity, evaluating safety and determining whether they can be developed into effective medicines.

AI systems can potentially accelerate some of these stages by helping researchers explore chemical structures, predict molecular interactions and identify promising candidates for experimental testing.

IsoDDE is designed to work across multiple therapeutic areas and drug modalities. The platform uses computational models to explore chemical possibilities and improve the design of molecules with desired properties.

The company says its AI systems are increasingly generating scientific advances that translate into improved molecular profiles for potential medicines. However, computational predictions must still be validated through laboratory experiments and clinical research before a drug can be considered safe and effective for patients.

First AI-Designed Drug Candidates Could Enter Clinical Testing

One of the most important objectives of the new funding is to move Isomorphic Labs’ first therapeutic programs toward clinical trials.

The company has reported positive preclinical results from its internal programs in oncology and immunology, as well as research conducted with pharmaceutical partners. Preclinical findings represent an important milestone, but they do not establish that a candidate medicine will work in humans.

Clinical trials will allow researchers to evaluate how experimental medicines behave in people, including their safety, tolerability, dosage requirements and potential therapeutic effectiveness.

Moving from AI-generated molecular designs to human testing represents a major test of Isomorphic’s technology. Drug candidates must pass extensive development and regulatory requirements, and many experimental treatments fail before reaching the market.

The company’s ability to advance candidates into clinical testing could therefore become an important measure of whether AI-powered drug discovery can deliver commercially viable medicines.

Isomorphic Labs Builds On DeepMind’s AlphaFold Breakthrough

Isomorphic Labs was founded in 2021 as a spinout from Google DeepMind, with the goal of applying AI advances to drug discovery and pharmaceutical development.

Its work builds on the broader scientific progress made through AlphaFold, DeepMind’s AI system that helped transform protein-structure prediction. Understanding the structure of proteins is important because proteins play central roles in biological processes, diseases and the development of many medicines.

Isomorphic aims to move beyond predicting biological structures and develop AI systems that can help researchers understand biological interactions and design molecules with specific therapeutic properties.

The company’s approach combines machine learning, computational biology, chemistry and pharmaceutical expertise. Its scientists work alongside AI researchers to develop and evaluate drug candidates, using computational methods to inform experiments and refine molecular designs.

The strategy is to build an integrated drug discovery platform rather than simply provide AI software to pharmaceutical companies.

Pharmaceutical Partnerships Strengthen Its Drug Pipeline

Isomorphic Labs has also established partnerships with major pharmaceutical companies, including Eli Lilly, Novartis and Johnson & Johnson.

These collaborations provide opportunities to apply AI drug-design technologies to specific therapeutic challenges and diseases. Pharmaceutical partnerships can also give AI drug discovery companies access to biological expertise, development capabilities, research resources and potential pathways toward commercialization.

The company is pursuing both partnered programs and internally developed therapeutic candidates. This combination could allow Isomorphic to expand the number of programs it works on while developing its own drug pipeline.

The new funding will support the expansion of this pipeline, the development of additional AI models and the infrastructure needed to progress drug candidates beyond early research.

AI Could Change The Economics Of Drug Development

Drug discovery has traditionally been expensive, time-consuming and uncertain. Developing a medicine can require years of research, billions of dollars in investment across the industry and extensive testing before regulators approve it.

AI-powered systems could potentially improve the early stages of the process by identifying promising targets, designing molecules and reducing the number of unsuccessful experiments.

The technology could help researchers explore chemical spaces that are difficult to investigate using conventional methods and generate new candidates for diseases with limited treatment options.

However, AI does not eliminate the scientific challenges of drug development. A molecule that performs well in simulations may fail in laboratory testing, behave differently in the human body or produce unacceptable side effects.

Clinical development remains a major hurdle, and the success of AI drug discovery will ultimately depend on whether the technology produces medicines that demonstrate meaningful benefits for patients.

The Bigger Picture

Isomorphic Labs’ $5 billion fundraising reflects a growing belief that artificial intelligence could become an important tool in pharmaceutical research. Investors are increasingly backing companies that combine advanced machine learning with biology, chemistry and drug development capabilities.

The industry is moving beyond using AI primarily for research assistance and toward building systems capable of influencing the design of new medicines. If these platforms can consistently produce drug candidates that succeed in clinical trials, they could reshape pharmaceutical research and create new approaches to treating complex diseases.

At the same time, the enormous investment highlights the risks involved. AI-designed drugs must overcome the same biological, regulatory and commercial challenges as traditional medicines. Funding and computational breakthroughs alone cannot guarantee clinical success.

Looking Ahead

Isomorphic Labs will use the new capital to accelerate the development of its AI drug-design engine, expand its research pipeline and build the clinical infrastructure needed to advance its first therapeutic programs. The company’s progress toward clinical trials will be closely watched by pharmaceutical companies, investors and researchers looking for evidence that AI can meaningfully shorten the drug discovery process. The next major milestone will be demonstrating that its computationally designed candidates can successfully progress through human testing.

The $5 billion round also places Isomorphic among the most heavily funded AI-driven drug discovery companies globally. Its long-term ambition is to build a platform capable of designing medicines at a scale and speed that conventional research methods cannot easily match. Whether that vision becomes reality will depend on the clinical results of its drug candidates, but the latest funding gives the company substantial resources to pursue that goal.

Get the day’s top stories in your inbox

One concise email. No spam, unsubscribe anytime.